Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Aurora Cannabis

Cronos Group

Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ:XXII) will license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON). The licensed intellectual property is designed to help advance the research and development of the biosynthesis of cannabinoids.

Aurora Cannabis, 22nd Century Group To License Biosynthesis Intellectual Property To Cronos

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis EDMONTON, AB, Dec. 14, 2021 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) ("22nd Century") announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group"), intended to assist in the advancement of research and development on the biosynthesis of cannabinoids. Biosynthesis, a process common in the pharmaceutical industry, involves using living micro-organisms to convert simple substances into complex compounds.

Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group

BUFFALO, N.Y., Dec. 10, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, announced today that it is fully engaged and ready to provide commercial support to the New Zealand Ministry of Health's Smokefree Aotearoa 2025 Action Plan, including supplying reduced nicotine content combustible cigarettes able to meet New Zealand's proposed standards.

22nd Century Ready to Provide Full Commercial Support to New Zealand's Plan to Reduce Nicotine Content of All Cigarettes

Flora Growth Corp

Valens Co. Commences Trading on NASDAQ under symbol $VLNS Public companies discussed in today's episode:

New Kid In Town — Cannabis Daily December 9, 2021

BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that Richard Fitzgerald has joined the Company as its Chief Financial Officer, effective November 15, 2021. John Franzino, the Company's previous Chief Financial Officer, has transitioned to Chief Administrative Officer, where he will be responsible for further developing the company's business processes and leading the Company's financial planning and analysis, operational finance, human resources, and information technology functions.

22nd Century Group Announces CFO Transition

BUFFALO, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, announced today that it strongly supports the nomination of Dr. Robert Califf as the next commissioner of the U.S. Food and Drug Administration (FDA). Califf is known to be a longtime proponent of tobacco control and supporter of the Agency's Comprehensive Plan for Tobacco and Nicotine Regulation.

22nd Century Group Applauds Califf Nomination as FDA Commissioner

BUFFALO, N.Y., Nov. 11, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, today announced that the Company will participate in the following virtual investor conferences during the month of November 2021:

22nd Century to Participate in Cowen and Roth Capital Investor Conferences in November 2021

22nd Century Group's (XXII) CEO Jim Mish on Q3 2021 Results - Earnings Call Transcript

Plant-based biotech company 22nd Century Group, Inc. (NASDAQ:XXII) reported its results on Thursday for the third quarter ended September 30, revealing net sales of $7.8 million for the period, up 6.9% from the prior year's period. Moreover, its year-to-date net sales totaled $23 million, up 11% from the corresponding period of last year.

22nd Century Group Reports Revenue Gains In Q3, Seeks To Monetize Its Hemp & Cannabis Plant Lines

BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, today reported results for the third quarter ended September 30, 2021, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century Group Reports Business Highlights and Financial Results for the Third Quarter 2021

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: 22nd Century Group (XXII) Q3 Earnings Expected to Decline

BUFFALO, N.Y., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science, will host a live webcast on Thursday, November 4, 2021, at 10:00 AM ET to discuss its 2021 third quarter results. 22nd Century will report the Company's third quarter 2021 results in a press release at 6:00 AM ET the same day.

22nd Century Group to Host Webcast to Provide Business Update and Discuss Third Quarter 2021 Results

BUFFALO, N.Y., Oct. 13, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and health and wellness through plant science, announced today that the Company's Vice President of Regulatory Science, John Pritchard, was invited and will participate as a panelist at the Food and Drug Law Institute (FDLI) Tobacco and Nicotine Products Regulation and Policy Conference as part of the event's session, “Reactor Panel: Assessing the Past, Present, and Future of the Comprehensive Plan,” on Wednesday, October 27, 2021, at 11:55 a.m. ET. The session will consider key points of the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products Director, Mitch Zeller's keynote address, and the current state of and future directions for FDA's Comprehensive Plan for product regulation, in particular the mandate to make all cigarettes “minimally or non-addictive.”

22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Implied Volatility Surging for 22nd Century (XXII) Stock Options

BUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced that the Company will participate in the following virtual investor conferences during the months of September and October 2021:

22nd Century to Participate in September and October 2021 Investor Conferences

The company says the total addressable market across all its businesses is $1.3 trillion.

22nd Century Group (Finally) Unveils Its Third Business

Canopy Growth

Greenlane Holdings

HEXO Corp

High Tide

WM Technology

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

What Happened with These 7 Marijuana Stocks This Week

Hops is an essential ingredient for brewing beer and has similar properties to cannabis.

22nd Century: Third Plant-Based Franchise And Record Q2 Revenues

Jazz Pharmaceuticals

Neither of them needs to sell marijuana to consumers to succeed.

Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks

22nd Century Group Inc (NASDAQ: XXII) is trading lower Monday as investors react to the company's announcement it will enter the specialty hops market. The global specialty hops market will be 22nd Century Group's third and newest plant franchise.

Why 22nd Century Group Shares Are Trading Lower Today

Geographic Expansion into Europe via the Netherlands Geographic Expansion into Europe via the Netherlands

22nd Century Group Enters Global Specialty Hops Market

22nd Century Group Inc (NASDAQ:XXII) announced its entry Monday into the global speciality hops market. What Happened: 22nd Century Group is a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science.

22nd Century Group Announces Franchise In Global Specialty Hops Market

Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company's Strategy, Technology Development, Commercialization, and Value Creation Efforts

22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors

AcelRx Pharmaceuticals

Jaguar Health

ReShape Lifesciences

Tellurian

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021

BUFFALO, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that its Chief Executive Officer, James A. Mish, is scheduled to present at the SNN Network Summer Virtual Event investor conference on Thursday, August 19, 2021 at 2:30 p.m. ET.

News for 22nd Century Group Stock (XXII)